Drug intelligence / Profile preview

denosumab + samarium-153 oxabifore

Development stage: Preclinical
Lead developer: Amgen
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous, Intravenous

Overview

A combination therapy used for the treatment of bone metastases. Denosumab is a monoclonal antibody that targets bone loss in cancer patients, while samarium-153 oxabifore is a radiopharmaceutical that targets osteoblastic bone lesions. The combination has been reported to be effective and safe for treating bone metastases, with possible synergistic effects. Samarium-153 oxabifore works by irradiating nerve fibers in bone lesions, providing pain relief for patients with metastatic bone disease.

Beyond the preview

Go deeper on denosumab + samarium-153 oxabifore.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on denosumab + samarium-153 oxabifore.

Explore the full profile